Prostate cancer Board decisions

The Veteran's effective dates for prostate cancer and type 2 diabetes have been granted from April 6, 2022.,The Veteran's prostate cancer increased rating issue and entitlement to TDIU are pending on remand.

The Veteran's claims for increased ratings for Chronic Lymphocytic Leukemia (CLL) and prostate cancer residuals were denied as there is no evidence of active disease or symptoms warranting a compensable rating.

The Veteran's claims for service connection were granted, but the effective dates for prostate cancer and erectile dysfunction were changed due to CUE. The Veteran is seeking earlier effective dates.

The Board has remanded the claims of service connection for prostate cancer residuals and lung cancer residuals due to procedural errors in the August 2022 rating decision.

The Board has denied the Veteran's claims for service connection for an acquired psychiatric disorder, a thoracolumbar spine disability, and residuals of prostate cancer. The evidence does not support finding that these conditions were incurred or aggravated by service.

The Board denied service connection for skin cancer, prostate cancer, and Alzheimer's type dementia due to a lack of evidence supporting herbicide or ionizing radiation exposure during service.

The Veteran's prostate cancer residuals are currently rated at 60 percent, and the Board has decided to remand the case for further development of private treatment records.

The Board has decided to remand the case due to a lack of adequate medical causal linkage opinion regarding whether the Veteran's prostate cancer was caused by or related to in-service TERA (jet fuel exposure). The examiner failed to address the Veteran's articles discussing the dangers of jet fuel exposure and the increased risk of prostate cancer in military pilots.

The Board has remanded the issue of service connection for prostate cancer due to a lack of explanation in the VA examiner's opinion regarding whether the Veteran's asbestos exposure caused his prostate cancer.

The Veteran's claim for service connection for prostate cancer is granted, and the effective date of this award is set at June 2, 2024.

The Veteran's tinnitus is related to in-service noise exposure and granted service connection.,Obstructive sleep apnea began during active service and was granted service connection.,Gastroesophageal reflux disease (GERD) and hiatal hernia are both linked to service, with symptoms beginning around the 1980s.,Service connection for diverticular disease and diverticulosis is remanded due to lack of direct evidence.,Prostate cancer is related to in-service toxic exposure risk activities involving hydrazine.

The Veteran's service-connected disabilities, including hypertension and other conditions, rendered him unable to secure or follow substantially gainful employment from April 14, 2021, until May 22, 2024. The Board granted a total disability rating based on individual unemployability during this period.

The Board has granted service connection for prostate cancer and diabetes mellitus, type 2 effective August 10, 2022 based on the PACT Act presumption of herbicide exposure. The claims for colon cancer, peripheral neuropathy of the left lower extremity, and peripheral neuropathy of the right lower extremity are remanded due to inadequate development.

The Veteran's claim for a separate rating for prostate cancer metastasized to lymphatic system is remanded due to a duty to assist error. The VA failed to obtain the Veteran's private treatment records and provide an adequate medical opinion regarding metastasis.

The Veteran's appeal for service connection for prostate cancer and sleep apnea is remanded due to inadequate development of exposure claims.

The Veteran's prostate cancer disability rating was reduced from 40 percent to 20 percent, effective November 14, 2024. The reduction is upheld as the evidence showed sustained material improvement in his ability to function under ordinary conditions of life and work.

The Veteran's service connection for prostate cancer was granted with an effective date of August 10, 2022, based on the PACT Act. The rating assigned is 40 percent.

The Board has granted service connection for erectile dysfunction, finding that it is secondary to the Veteran's service-connected prostate cancer.

The Veteran's prostate cancer is related to his military service, but the Board has determined that there was not enough evidence to support this claim and needs further investigation.

The Board denied service connection for right and left knee disabilities, as well as an eyesight disability. The Veteran was not found to have a current diagnosis of these conditions.,Service connection for prostate cancer due to participation in a toxic exposure risk activity (TERA) is also denied.